Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.

@article{Ferdinandi2007NonclinicalPA,
  title={Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue.},
  author={E. Ferdinandi and P. Brazeau and K. High and B. Procter and S. Fennell and P. Dubreuil},
  journal={Basic & clinical pharmacology & toxicology},
  year={2007},
  volume={100 1},
  pages={
          49-58
        }
}
TH9507, an analogue of human growth hormone-releasing factor (hGRF1-44NH2) minimally modified by addition of a trans-3-hexenoyl moiety to Tyr1 of the amino acid sequence, was found to be resistant to dipeptidyl aminopeptidase-IV deactivation. Compared to natural hGRF1-44NH2, the modification slowed the in vitro degradation of the peptide in rat, dog and human plasma and prolonged the in vivo plasma elimination kinetics of immunoreactive TH9507. Plasma growth hormone and insulin-like growth… Expand
View on PubMed
onlinelibrary.wiley.com
21 Citations
Highly Influential Citations
2
Background Citations
12

21 Citations

Citation Type

Citation Type

Tesamorelin, a human growth hormone releasing factor analogue
  • 4
Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects
  • 1
Spotlight on Tesamorelin in HIV-Associated Lipodystrophy
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
  • 13
  • Highly Influenced
Tesamorelin: a synthetic growth hormone-releasing factor analog for the treatment of HIV-associated lipodystrophy
Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides
  • 113
Growth hormone secretagogues: history, mechanism of action, and clinical development
  • 5
Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS
  • 14
Strategic Approaches to Optimizing Peptide ADME Properties
  • L. Di
  • Chemistry, Medicine
  • The AAPS Journal
  • 2014
  • 209
Urothelial overexpression of insulin‐like growth factor‐1 increases susceptibility to p‐cresidine‐induced bladder carcinogenesis in transgenic mice
  • 13
...
1
2
3
...

References

SHOWING 1-10 OF 32 REFERENCES
Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.
  • 15
Growth hormone response induced by synthetic human growth hormone-releasing factor (1-44) in healthy dogs.
  • 8
In vitro metabolic degradation of a bovine growth hormone-releasing factor analog Leu27-bGRF(1-29)NH2 in bovine and porcine plasma. Correlation with plasma dipeptidylpeptidase activity.
  • 29
Effect of dose and frequency of administration of a potent analog of human growth hormone-releasing factor on hormone secretion and growth in pigs.
  • 59
Pharmacological and Toxicological Effects of Chronic Porcine Growth Hormone Administration in Dogs
  • 51
  • PDF
Biosynthetic human growth hormone: subchronic toxicity studies in rats and monkeys.
  • 29
Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted at position-1.
  • 42
Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus.
  • 135
  • PDF
Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour
  • 1,037
Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues
  • 49
...
1
2
3
4
...